메뉴 건너뛰기




Volumn 7, Issue 2, 2006, Pages 152-154

Extend PIX301: A phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma

Author keywords

Anthracyclines; Cardiac toxicity; Single agent therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PIXANTRONE; RITUXIMAB; UNCLASSIFIED DRUG;

EID: 33750147820     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.055     Document Type: Article
Times cited : (7)

References (17)
  • 1
    • 33746904664 scopus 로고    scopus 로고
    • Clinical practice guidelines in oncology: Non-Hodgkin's lymphoma
    • National Comprehensive Cancer Network [Web site]. Available at: Accessed June 29
    • National Comprehensive Cancer Network [Web site]. Clinical practice guidelines in oncology: non-Hodgkin's lymphoma. Available at: www.nccn.org. Accessed June 29, 2006.
    • (2006)
  • 2
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
    • (2002) N Engl J Med , vol.346 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 3
    • 0017132731 scopus 로고
    • Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
    • McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38:1484-1493.
    • (1976) Cancer , vol.38 , pp. 1484-1493
    • McKelvey, E.M.1    Gottlieb, J.A.2    Wilson, H.E.3
  • 4
    • 0032951328 scopus 로고    scopus 로고
    • International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury
    • Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17:423-429.
    • (1999) J Clin Oncol , vol.17 , pp. 423-429
    • Shipp, M.A.1    Abeloff, M.D.2    Antman, K.H.3
  • 5
    • 0023818185 scopus 로고
    • Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
    • Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-122.
    • (1988) Blood , vol.71 , pp. 117-122
    • Velasquez, W.S.1    Cabanillas, F.2    Salvador, P.3
  • 6
    • 0028261089 scopus 로고
    • ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
    • Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169-1176.
    • (1994) J Clin Oncol , vol.12 , pp. 1169-1176
    • Velasquez, W.S.1    McLaughlin, P.2    Tucker, S.3
  • 7
    • 0032761285 scopus 로고    scopus 로고
    • Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
    • Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776-3785.
    • (1999) J Clin Oncol , vol.17 , pp. 3776-3785
    • Moskowitz, C.H.1    Bertino, J.R.2    Glassman, J.R.3
  • 8
    • 0028790440 scopus 로고
    • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
    • Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
    • (1995) N Engl J Med , vol.333 , pp. 1540-1545
    • Philip, T.1    Guglielmi, C.2    Hagenbeek, A.3
  • 9
    • 0002421959 scopus 로고
    • CHOP is curative in 30% of patients with large cell lymphoma: A twelve-year Southwest Oncology Group follow-up
    • In: Skarin AT, ed. New York, NY: Park Row
    • Coltman C, Dahlberg S, Jones SE, et al. CHOP is curative in 30% of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow-up. In: Skarin AT, ed. Advances in Cancer Chemotherapy. New York, NY: Park Row; 1986:71-78.
    • (1986) Advances in Cancer Chemotherapy , pp. 71-78
    • Coltman, C.1    Dahlberg, S.2    Jones, S.E.3
  • 10
    • 0036234795 scopus 로고    scopus 로고
    • A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma
    • Webb MS, Saltman DL, Connors JM, et al. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43:975-982.
    • (2002) Leuk Lymphoma , vol.43 , pp. 975-982
    • Webb, M.S.1    Saltman, D.L.2    Connors, J.M.3
  • 11
    • 0032784782 scopus 로고    scopus 로고
    • Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
    • Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3786-3792.
    • (1999) J Clin Oncol , vol.17 , pp. 3786-3792
    • Fossa, A.1    Santoro, A.2    Hiddemann, W.3
  • 12
    • 0032936294 scopus 로고    scopus 로고
    • Preliminary results on the activity of oxaliplatin (L-OHP) in refractory /recurrent non-Hodgkin's lymphoma patients
    • Germann N, Brienza S, Rotarski M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10:351-354.
    • (1999) Ann Oncol , vol.10 , pp. 351-354
    • Germann, N.1    Brienza, S.2    Rotarski, M.3
  • 13
    • 0025906889 scopus 로고
    • Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease
    • Silver RT, Case DC Jr, Wheeler RH, et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9:754-761.
    • (1991) J Clin Oncol , vol.9 , pp. 754-761
    • Silver, R.T.1    Case Jr., D.C.2    Wheeler, R.H.3
  • 14
    • 0029121860 scopus 로고
    • Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives
    • De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 1995; 48:30-38.
    • (1995) Mol Pharmacol , vol.48 , pp. 30-38
    • De Isabella, P.1    Palumbo, M.2    Sissi, C.3
  • 15
    • 0035746666 scopus 로고    scopus 로고
    • BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity
    • Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001; 87:407-416.
    • (2001) Tumori , vol.87 , pp. 407-416
    • Beggiolin, G.1    Crippa, L.2    Menta, E.3
  • 16
    • 0034988022 scopus 로고    scopus 로고
    • Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma
    • Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001; 12:661-667.
    • (2001) Ann Oncol , vol.12 , pp. 661-667
    • Borchmann, P.1    Schnell, R.2    Knippertz, R.3
  • 17
    • 0141649441 scopus 로고    scopus 로고
    • Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas
    • Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003; 88:888-894.
    • (2003) Haematologica , vol.88 , pp. 888-894
    • Borchmann, P.1    Morschhauser, F.2    Parry, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.